David Berry is a general partner with venture capital firm Flagship Pioneering. In recent years, he has co-founded companies that are developing microbiome products for both human therapeutics and agricultural applications. He spoke with Xconomy during Biotech Week Boston in September about the promise of microbiome medicine and the challenges of developing a new class of drugs.

• Share on Facebook
• Share on Twitter
• LinkedIn
• Email
• Reprints

Trending on Xconomy

• Moderna Raises $604M and Nails Down Biotech’s Biggest IPO Ever
• Synthorx Gets $131M in Upsized IPO for Synthetic Biology Drugs
• Cord Cutting: How to Get High-Speed Internet Service Without Cable